Loading
Everything in development, the open problems and what is being done about them, the roadmaps, and what changed on this record.
What is in development for Vaginal cancer, drawn from the whole corpus: 5 items. Drugs are grouped by the most advanced trial phase they have reached anywhere; approved treatments sit under standard of care. Technologies are the methods being tested for this cancer, trials are the studies recorded here, and ideas are proposals not yet in a trial.
No dedicated randomised trials; HPV-basket immunotherapy trials and international rare-tumour registries are filling the gap.
Optimal brachytherapy technique and dose for vaginal primaries; MRI-guided adaptive brachytherapy series are maturing.
Late toxicity and sexual function after pelvic radiotherapy; survivorship programmes are the response.
Nothing recorded yet.
Nothing recorded yet.
Also on OnCo: Side effects by symptom · Immune-related side effects · Toxicity compare · Survivorship planner.
Surveillance of women treated for CIN 3 to catch VAIN early.
Dated changes read from the records linked to this cancer: approvals, regulatory steps, reported trials, guideline versions and milestones. Newest first; no date is inferred.
On EdgeAll 8 changes by month →When this page itself was last checked or edited.
PFS HR 0.
A milestone in how this cancer is treated.
OS 26.
Extended in practice to HPV-associated vaginal cancer.
Protects against the HPV types that cause most vaginal, cervical and vulvar cancers.